These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20043216)

  • 1. Experience with sorafenib and the elderly patient.
    Dutcher JP; Tannir N; Bellmunt J; Escudier B
    Med Oncol; 2010 Dec; 27(4):1359-70. PubMed ID: 20043216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
    Eisen T; Oudard S; Szczylik C; Gravis G; Heinzer H; Middleton R; Cihon F; Anderson S; Shah S; Bukowski R; Escudier B;
    J Natl Cancer Inst; 2008 Oct; 100(20):1454-63. PubMed ID: 18840822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sorafenib(Nexavar)].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
    Castagneto B; Stevani I; Giorcelli L; Montefiore F; Bigatti GL; Pisacco P; Cosimi MF
    Med Oncol; 2011 Dec; 28(4):1384-8. PubMed ID: 20552299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
    Tanigawa G; Kawashima A; Yamaguchi S; Nishimura K; Miyoshi S; Kajikawa J; Meguro N; Yosioka T; Oka T; Hara T; Takayama H; Nonomura N;
    Jpn J Clin Oncol; 2011 Nov; 41(11):1265-70. PubMed ID: 21965163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
    Lekili M; Muezzinoglu T; Nese N; Temeltas G
    J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib: in advanced renal cancer.
    McKeage K; Wagstaff AJ
    Drugs; 2007; 67(3):475-83; discussion 484-5. PubMed ID: 17335301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in advanced clear-cell renal-cell carcinoma.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
    N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
    Massard C; Zonierek J; Gross-Goupil M; Fizazi K; Szczylik C; Escudier B
    Ann Oncol; 2010 May; 21(5):1027-31. PubMed ID: 19850637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
    Beck J; Bellmunt J; Escudier B
    Med Oncol; 2011 Dec; 28(4):1379-83. PubMed ID: 20593250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
    Trask PC; Bushmakin AG; Cappelleri JC; Tarazi J; Rosbrook B; Bycott P; Kim S; Stadler WM; Rini B
    J Cancer Surviv; 2011 Sep; 5(3):255-62. PubMed ID: 21476015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
    Valcamonico F; Ferrari V; Amoroso V; Rangoni G; Simoncini E; Marpicati P; Vassalli L; Grisanti S; Marini G
    J Neurooncol; 2009 Jan; 91(1):47-50. PubMed ID: 18712279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
    Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
    Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib rechalenge in metastatic renal cell carcinoma.
    Porta C; Paglino C; Imarisio I
    BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
    [No Abstract]   [Full Text] [Related]  

  • 20. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
    Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.